POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions (K+) for maintenance of electrolyte balance. Dextrose (glucose) provides caloric support and is metabolized via glycolysis and oxidative phosphorylation. Sodium chloride provides sodium and chloride ions for fluid and electrolyte balance.
| Metabolism | Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, with release of energy. Potassium and sodium are excreted primarily by the kidneys. |
| Excretion | Potassium is primarily excreted renally (about 90%) via glomerular filtration and tubular secretion in the distal nephron; approximately 10% is eliminated in feces via gastrointestinal secretion. |
| Half-life | The terminal elimination half-life of potassium is approximately 9 hours (range 7–11 hours) in patients with normal renal function. Clinically, this means steady state is achieved after about 45 hours of continuous infusion; half-life is prolonged in renal impairment. |
| Protein binding | Potassium is minimally bound to plasma proteins (<5%); binding is negligible and not clinically relevant. |
| Volume of Distribution | Approximately 0.2–0.4 L/kg in adults (total body water is ~0.6 L/kg but potassium Vd reflects exchangeable pool). Clinical meaning: distributes primarily in intracellular fluid; changes in Vd can occur in acid-base disturbances. |
| Bioavailability | Oral potassium chloride: bioavailability is approximately 90–100% when taken with food; absorption is rapid and complete from the gastrointestinal tract. IV administration: 100% bioavailability. |
| Onset of Action | Intravenous infusion: correction of hypokalemia begins within minutes; peak effect on serum potassium occurs within 1–2 hours after infusion rate adjustment. Oral administration: onset is variable, typically 30–60 minutes after ingestion. |
| Duration of Action | Duration after IV infusion is 4–6 hours depending on infusion rate and renal function; continuous infusion is often required for sustained correction. Oral potassium salts have a duration of effect lasting 6–8 hours after a single dose. |
| Molecular Weight | 74.55 |
Intravenous infusion at a rate not exceeding 10 mEq/hour, typical adult dose 20 mEq once daily or as directed by serum potassium levels.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid use or reduce dose by 75% with close monitoring. |
| Liver impairment | No specific dose adjustment recommended; use with caution in severe hepatic impairment due to risk of electrolyte disturbances. |
| Pediatric use | 0.5-1 mEq/kg/day intravenously, not to exceed 20 mEq/hour; adjust based on serum potassium levels. |
| Geriatric use | Initiate at lower end of dosing range (10-20 mEq/day); monitor renal function and potassium levels closely due to age-related decline in renal function. |
| 1st trimester | Potassium chloride is essential for cellular function; use only if clearly needed. No teratogenic effects reported at therapeutic doses; however, hyperkalemia may occur and should be avoided. |
| 2nd trimester | Same as t1; monitor serum potassium closely due to increased renal clearance in pregnancy. |
| 3rd trimester | Same as t1; use caution as hyperkalemia can affect uterine contractility. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta by active transport; fetal serum potassium is slightly higher than maternal. No known harm at therapeutic doses. |
| Breastfeeding | Potassium is a normal constituent of breast milk; intravenous administration may increase milk potassium slightly. No adverse effects reported in infants. Use with caution if maternal potassium levels become elevated. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride at therapeutic doses is not known to be teratogenic. Dextrose and sodium chloride are physiologic and not teratogenic at standard concentrations. However, severe electrolyte disturbances (e.g., hyperkalemia, hypokalemia, hypernatremia) may pose risks, including fetal arrhythmias or growth disturbances. In first trimester, no specific malformations are documented. In second and third trimesters, maternal electrolyte imbalance can affect fetal homeostasis. It is recommended to maintain normal electrolyte levels. |
| Fetal Monitoring | Monitor maternal serum potassium, glucose, and sodium levels. Monitor serum osmolality if high dextrose concentrations. Fetal monitoring (e.g., heart rate) is indicated if maternal electrolyte imbalances occur or if infusion is rapid. Assess maternal renal function, fluid status, and signs of hypervolemia or electrolyte disturbances. For high-risk pregnancies, consider periodic ultrasound for fetal growth. |
| Fertility Effects | No specific adverse effects on fertility are reported for potassium chloride, dextrose, or sodium chloride at therapeutic doses. Electrolyte disturbances (e.g., hypokalemia, hypernatremia) from underlying conditions may impair reproductive function, but these are not direct effects of the drug. For patients undergoing assisted reproduction, maintenance of normal electrolyte balance is recommended. |
■ FDA Black Box Warning
Concentrated potassium solutions (including this product) must be diluted prior to administration to avoid fatal hyperkalemia. Rapid infusion can cause cardiac arrhythmias and cardiac arrest.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguriaAcute dehydrationAdrenal insufficiencyConcomitant use of potassium-sparing diuretics without monitoring
| Precautions | Monitor serum potassium levels frequently during therapy, Use caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Do not administer rapidly or via Y-site with other medications, Solutions containing dextrose may cause hyperglycemia in diabetic patients, Risk of fluid overload in patients with congestive heart failure or renal failure |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes, spinach, avocados) and potassium-containing salt substitutes during treatment due to risk of hyperkalemia. Also be cautious with licorice (glycyrrhizin) as it can affect potassium levels. |
| Clinical Pearls | Use central line if peripheral access is inadequate due to high osmolality (≈800 mOsm/L) from dextrose and electrolytes. Monitor serum potassium closely during infusion; rate should not exceed 10 mEq/h (or 20 mEq/h in severe hypokalemia) via central line. Do not administer undiluted; this is a premixed solution for IV infusion only. Contraindicated in hyperkalemia, severe renal impairment, or in patients with potassium-sparing diuretic use. |
| Patient Advice | This medication is given intravenously (IV) to replace potassium and provide fluids and sugar. · Inform your nurse immediately if you experience pain, redness, or swelling at the IV site. · Report any muscle weakness, numbness, tingling, or irregular heartbeat. · Do not consume potassium-rich foods or salt substitutes without consulting your doctor. · Tell your healthcare provider about all medications you take, especially heart or blood pressure medicines. |
Loading safety data…